Seven products already selling. One system built for two markets.

MED.PCENT / 7-SKU REBRAND + 3 NEW SKUS

KOREA · CHINA / ONE CORE · TWO ROUTES

Products and content were already selling in China. Korea entry required more than translation: the roles, efficacy readability, price architecture, evidence and channel priority of all seven SKUs had to be reassessed.

We did not design Korea and China as separate brands. Formula, ingredient, sensorial experience, package silhouette and proof became one product truth; regulation, buying language, price, content and distribution order were routed by market.

• Korea × China market, competitor, review and price databook
• Product-truth and market-fit audit across 7 SKUs
• KEEP · MESSAGE RESET · PACK RESET · FORMULA REDEVELOP classification
• 10-SKU role, routine and price-ladder portfolio
• Commercial, formula and sensorial briefs for 3 new SKUs
• Manufacturer bidding, samples R1–R3, cost and MOQ control
• Ingredient IP, clinical, claim and PDP evidence system
• Korea-China entry candidates and integrated 28-week WBS

For each new SKU, allowable cost is reverse-engineered from target retail, channel fee and promotion capacity. Manufacturer comparison, provisional formula, sensorial review, up to three sample rounds and golden-sample approval are controlled in one decision log.

• KOREA: NAVER · D2C VALIDATION
• KOREA: OLIVE YOUNG ENTRY HYPOTHESIS
• KOREA: MUSINSA BEAUTY EXPANSION
• CHINA: KOL · KOC · MCN · TP/DISTRIBUTION REVIEW

• 7× SKU diagnostic cards
• 10-SKU portfolio map
• Korea × China opportunity map
• Claim–Evidence Matrix
• Up to five clinical-theme briefs
• Ingredient-IP platform brief
• 10× PDP selling-point sheets

Korea requires efficacy, reason-to-use and proof to read in three seconds. China requires a route from content seed to search and conversion. The same product truth is expressed in each market's buying language.

The masterplan connects the rebrand of seven existing products, PM for three new products, shared ingredient and evidence IP, and Korea-China market-entry preparation across 28 weeks. Purchase, production, testing, media and sales outcomes remain separately scoped execution variables.